Table 2. Survival Function at Years 1 and 2 for the Biologic Cohorts Stratified by Reason for Discontinuationa.
| Reasons for drug discontinuation | Adalimumab (n = 6607) | Secukinumab (n = 2677) | Ustekinumab (n = 5405) | Ixekizumab (n = 703) | Guselkumab (n = 730) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total participants/No. of discontinuations | Survival function (95% CI) | Total participants/No. of discontinuations | Survival function (95% CI) | Total participants/No. of discontinuations | Survival function (95% CI) | Total participants/No. of discontinuations | Survival function (95% CI) | Total participants/No. of discontinuations | Survival function (95% CI) | |
| Overall | ||||||||||
| Year 1 | 4693/1629 | 0.75 (0.74-0.76) | 1942/467 | 0.81 (0.80-0.83) | 4304/789 | 0.85 (0.84-0.86) | 410/119 | 0.80 (0.77-0.83) | 408/75 | 0.88 (0.85-0.90) |
| Year 2 | 3533/903 | 0.60 (0.59-0.61) | 1262/342 | 0.66 (0.64-0.68) | 3308/561 | 0.73 (0.72-0.75) | 170/78 | 0.61 (0.57-0.66) | 99/23 | 0.80 (0.76-0.84) |
| Ineffectiveness | ||||||||||
| Year 1 | 4377/1164 | 0.81 (0.80-0.82) | 1859/336 | 0.86 (0.85-0.87) | 4152/582 | 0.89 (0.88-0.89) | 392/80 | 0.86 (0.83-0.89) | 406/34 | 0.94 (0.92-0.96) |
| Year 2 | 3345/260 | 0.76 (0.75-0.77) | 1201/205 | 0.75 (0.74-0.77) | 3184/245 | 0.83 (0.82-0.84) | 165/39 | 0.75 (0.71-0.79) | 99/6 | 0.92 (0.89-0.94) |
| Adverse events | ||||||||||
| Year 1 | 4524/561 | 0.91 (0.90-0.91) | 1920/160 | 0.94 (0.92-0.94) | 4235/280 | 0.94 (0.94-0.95) | 404/51 | 0.92 (0.89-0.94) | 407/23 | 0.96 (0.94-0.98) |
| Year 2 | 3411/136 | 0.88 (0.87-0.89) | 1247/54 | 0.90 (0.89-0.92) | 3254/123 | 0.91 (0.91-0.92) | 166/13 | 0.87 (0.84-0.90) | 99/10 | 0.93 (0.91-0.95) |
a
Survival serves as a proxy for effectiveness and safety.